Literature DB >> 15618164

Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.

Samuel T Test1, Joyce K Mitsuyoshi, Yong Hu.   

Abstract

Complement activation plays a critical role in the immune response to T-cell-dependent and T-cell-independent antigens. However, the effect of conjugation of T-cell-dependent protein carriers to T-cell-independent type 2 antigens on the requirement for complement in the humoral immune response to such antigens remains unknown. We studied the role of complement activation on the antibody response of BALB/c mice immunized with the T-cell-independent type 2 antigen serotype 14 pneumococcal capsular polysaccharide (PPS14), either in unmodified form or conjugated to ovalbumin (OVA). In mice immunized with either PPS14 or PPS14-OVA, depletion of endogenous complement at the time of primary immunization by treatment with cobra venom factor (CVF) diminished serum anti-PPS14 concentrations after primary immunization but enhanced antibody responses after secondary immunization. The secondary immunoglobulin G (IgG) anti-PPS14 antibody response after immunization with PPS14-OVA was especially enhanced by complement depletion, was observed at doses as low as 0.2 mug of antigen, and was maximal when CVF was administered within 2 days of immunization. The avidity and opsonophagocytic functions of IgG anti-PPS14 antibodies were comparable in mice immunized with PPS14-OVA with or without complement depletion. Serum anti-PPS14 antibody concentrations were near normal, and the enhancing effects of CVF treatment on the secondary anti-PPS14 antibody response were also apparent in splenectomized mice immunized with PPS14-OVA. These results demonstrate that complement activation can have distinct effects on the primary and secondary antibody responses to a T-cell-independent type 2 antigen, either unmodified or conjugated to a T-cell-dependent protein carrier. These differences should be taken into consideration when using complement to modulate the immune response to vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618164      PMCID: PMC538989          DOI: 10.1128/IAI.73.1.277-286.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

Review 1.  The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity.

Authors:  D T Fearon; R H Carter
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

2.  Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod.

Authors:  M Monsigny; C Petit; A C Roche
Journal:  Anal Biochem       Date:  1988-12       Impact factor: 3.365

3.  Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes.

Authors:  R H Carter; M O Spycher; Y C Ng; R Hoffman; D T Fearon
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

Review 4.  T cell-independent antigens type 2.

Authors:  J J Mond; A Lees; C M Snapper
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

5.  Characteristics of immune responses to native and protein conjugated pneumococcal polysaccharide type 14.

Authors:  G P van den Dobbelsteen; H Kroes; E P van Rees
Journal:  Scand J Immunol       Date:  1995-03       Impact factor: 3.487

6.  Inhibition of immunological memory and T-independent humoral responses by monoclonal antibodies specific for murine complement receptors.

Authors:  E J Wiersma; T Kinoshita; B Heyman
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

7.  Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration.

Authors:  G C Tsokos; J D Lambris; F D Finkelman; E D Anastassiou; C H June
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

8.  Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction.

Authors:  S Gustavsson; T Kinoshita; B Heyman
Journal:  J Immunol       Date:  1995-06-15       Impact factor: 5.422

9.  Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo.

Authors:  G Thyphronitis; T Kinoshita; K Inoue; J E Schweinle; G C Tsokos; E S Metcalf; F D Finkelman; J E Balow
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

10.  Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2.

Authors:  A W Griffioen; G T Rijkers; P Janssens-Korpela; B J Zegers
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

View more
  5 in total

1.  Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide.

Authors:  Joyce K Mitsuyoshi; Yong Hu; Samuel T Test
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

2.  CD21/35 promotes protective immunity to Streptococcus pneumoniae through a complement-independent but CD19-dependent pathway that regulates PD-1 expression.

Authors:  Karen M Haas; Jonathan C Poe; Thomas F Tedder
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

3.  Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice.

Authors:  Haijun Tian; Sarah Weber; Peter Thorkildson; Thomas R Kozel; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2009-01-21       Impact factor: 3.441

Review 4.  More than a Pore: Nonlytic Antimicrobial Functions of Complement and Bacterial Strategies for Evasion.

Authors:  Elisabet Bjanes; Victor Nizet
Journal:  Microbiol Mol Biol Rev       Date:  2021-01-27       Impact factor: 11.056

5.  Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei.

Authors:  Gregory C Whitlock; Roman A Lukaszewski; Barbara M Judy; Slobodan Paessler; Alfredo G Torres; D Mark Estes
Journal:  BMC Immunol       Date:  2008-09-29       Impact factor: 3.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.